J&J’s One Touch Via Provides $1 Billion Market Opportunity

J&J’s One Touch Via Insulin Patch Is Ready For Launch:

J&J Plans to launch its One Touch Via wearable insulin patches in the U.S. by early 2017. The company delayed the launch of the strips, which got FDA approval in 2012, while it streamlined and automated the production processes.

Why This Product Will Sell Well?

• Insulin patches can be worn on the the patient’s abdomen underneath clothing, and patients can take the therapy in two unit increments by the click of a button. This increases the likelihood of patient compliance due to its ease of use and privacy, unlike insulin pens.
• Originally J&J’s Insulin patches (One Touch Via) was developed for people with Type 2 diabetes but now many with Type 1 diabetes will be able to use it as well.
• One Touch Via wearable patches are expected to be cheaper than the pens and syringes that are now used regularly by diabetes patients
• These are first of its kind patches through which insulin can be directly injected into the body.

Market Opportunity Sales Potential Of $1 Billion

Data Sources:

[1] Statistics About Diabetes, American Diabetes Association, July 05,2016

[2] Johnson & Johnson Consumer and Medical Devices Business Review (Slide 155 & 161), Johnson & Johnson, May 18,2016

Sources:

[1] J&J’s insulin patch finally heading for launch, In-Pharma Technologist, July 05, 2016

[2] J&J’s OneTouch Via Mealtime Insulin Delivery Device + First Look at its Artificial Pancreas Device, Diatribe, June 06,2016

Have more questions about Johnson & Johnson? See the links below.

• Drugs, Devices, Consumer: What’s Johnson & Johnson’s Revenue and Earnings breakdown?
• How Increased Focus On Pharmaceuticals In The Last 5 Years Has Helped J&J?
• By How Much Can J&J’s Revenue And EBITDA Grow Over The Next 3 Years?
• What Percentage Of Its Revenue Could J&J Lose Solely Due To Patent Losses Over The Next 5 Years?
• If Remicade Biosimilar Hits The U.S. Market In 2017, Does J&J Face Any Meaningful EPS Decline?
• Considering Recent Divestitures, Should J&J Trim Its Medical Devices Segment Further?
• Despite The Revenue Fall, J&J’s Business Has A Silver Lining
• Three Things To Watch Out For J&J This Year
• Here Is Why J&J Could See Growth As It Reports Its Q1 2016 Results
• Why We Are Slightly Bullish On J&J?

Notes:

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology